Summary The DNA repair enzyme, 06-alkylguanine-DNA-alkyltransferase (ATase), is thought to be the principal mechanism controlling resistance to nitrosoureas and related alkylating agents. We compared the sensitivities of five human testis and five bladder tumour cell lines to two nitrosoureas (N-nitroso-Nmethylurea (MNU) and mitozolomide) with cellular levels of ATase. Enzyme levels ranged from 3 to 206 fmol mg-1 protein (0.1 x 104 to 5.1 x 104 molecules/cell) in the testis lines and from 11 to 603 fmol mg-1 (0.4 x 104 to 9.1 x 104 molecules/cell) in the bladder lines. Based on IC5Os in an MTT assay, the testis tumour cell lines were, on average, four times more sensitive to MNU and six times more sensitive to mitozolomide than the bladder cell lines. The cytotoxicities of MNU and mitozolomide were closely related (R = 0.9). In the testis cell lines ATase activity (molecules/cell) was related to IC50s for mitozolomide (R = 0.97) but not MNU (R = 0.78). In the bladder cell lines and overall, ATase activity correlated with cellular sensitivity to neither agent. Relatively high levels of resistance occurred in cells expressing low levels of ATase, and amongst cell lines expressing high levels of ATase, large differences in IC5Os were observed. These results support the suggestion that resistance to nitrosoureas can be mediated by mechanisms other than ATase and that at relatively high levels of expression, ATase does not confer resistance in proportion to its activity.
using combination chemotherapy (Peckham, 1988) . We have shown that testis tumour cell lines retain sensitivity to anticancer agents in vitro (Walker et al., 1987; Masters et al., 1990) , reflecting the clinical response of these tumours. To determine whether the sensitivity of testis tumour cells to nitrosoureas might be related to ATase, we compared ATase levels and cellular sensitivities to two nitrosoureas, MNU and mitozolomide, in five human testis and five bladder cancer cell lines, and two cisplatin-resistant sublines .
These two compounds were chosen as models for all mono-and bifunctional nitrosoureas. They were selected specifically because their mechanisms of action are wellcharacterised and their toxicity would be expected to be associated with ATase levels, if this enzyme controls sensitivity in these cells (Gibson et al., 1984; Stevens et al., 1984; Pegg, 1990) .
Materials and methods
Measurement of cytotoxicity of methylating and chloroethylating agents The cytotoxicities of MNU (Sigma Chemical Co. Ltd., Poole, UK) and mitozolomide (May & Baker, Dagenham, UK) against the bladder cell lines RT1 12, RT1 12-CP, RT4, HT1376, HT1197 and MGH-U1 and the testis cell lines SuSa, SuSa-CP, 1618K, Tera II, GH and GCT27, were compared using the MTT assay, as described , except that the concentration of MTT (Sigma) used was 4mgml-'. Both drugs were dissolved in DMSO and stored at -20°C. For each experiment, an aliquot was thawed and rapidly diluted to the appropriate concentration in complete medium and immediately added to the cells. Toxicity of MNU was measured over the range 0.25-200 gig ml-' and toxicity of mitozolomide over the range 0.1 -50 j.g ml-'. Drug was added 24 h after the cells were plated, and left for a further 6 days. A minimum of three separate experiments were performed for each cell line and each drug. Dose responses were plotted and IC50 values (i.e. concentration of drug which reduces the absorbance to 50% of the control) were calculated by linear regression analysis of the linear part of the graph. ATase assays were carried out essentially as described (Morten & Margison, 1988) , except that the total incubation volume was 400 yl. Positive and negative controls were included: the positive control was a range of six volumes of a semi-purified extract of E. coli containing the plasmid p061 which carries the E. coli ogt ATase gene (Margison et al., 1985) (Bradford, 1976 lower than all the testis cell lines except GCT27 (3.3 fmol mg-'). When ATase activities were calculated as molecules/ cell, the same pattern was observed (see Table I ).
The relationships between IC50s and ATase levels (molecules/cell) in the testis and bladder tumour cell lines are shown in Figure 1 Low ATase activity is associated with sensitivity to CNUs in human and murine cell lines in some studies (Day et al., 1980; Bodell et al., 1986; Jelinek et al., 1988; Smith & Brent, 1989) but not others (Samson & Linn, 1987; Maynard et al., 1989) . It is difficult to relate actual ATase levels to sensitivity or resistance, because the ATase levels associated with resistance to CNUs differ widely between studies. An ATase level as low as 33 fmol mg-I protein correlated with resistance to the cytotoxic effects of MTIC in human melanoma cell lines (Maynard et al., 1989) . Five melanoma cell lines with ATase levels of 13 fmol mg'-I or lower were 4 to 17-fold more sensitive to MTIC than four melanoma cell lines with ATase activity of at least 33 fmol mg'-protein. A small difference in ATase activity was associated with a relatively large difference in sensitivity. In contrast, a human rhabdomyosarcoma cell line containing 3800 fmol ATase mg-' protein was only 5-6 times more resistant to CNUs than a rhabdomyosarcoma cell line which lacked measureable ATase (Smith & Brent, 1989) . In this case, a very large difference in ATase activity was associated with a relatively modest difference in CNU sensitivity. Thus it seems unlikely that the very small difference in ATase activity between RT4 (bladder) and SuSa or 1618K (testis) cell lines would alone account for the 5-6-fold difference in mitozolomide sensitivity in this study.
Whilst in the testis cell lines there appears to be a reasonable correlation between ATase levels (expressed/cell) and the IC5Os for mitozolomide, there are several possible mechanisms besides ATase level which could explain differential sensitivity to CNUs between bladder and testis lines and within the bladder lines. These include differences in uptake of drug and binding to intracellular molecules other than DNA, such as glutathione. Resistant cells may be better able to tolerate or-bypass the 06-alkylguanine lesions (Fox & Roberts, 1987 (Boyle et al., 1987) . This is probably by nucleotide excision repair, the process which recognises bulky adducts including uv-induced pyrimidine dimers. In the case of V79/79 cells it has been shown that 06-methylguanine can also be removed from DNA, presumably by an excision repair process (Boyle et al., 1987) . (Margison & O'Connor, 1989) . Besides 06-alkylguanine, other lesions produced in DNA include N7-alkylguanine and N3-alkyladenine. For methylating agents, N3-methyladenine, but not 06-methylguanine or N7-methylguanine (the major product), blocks DNA synthesis (Margison & O'Connor, 1989) .
ATase levels and MNU and mitozolomide sensitivities were measured in cisplatin-resistant sublines of SuSa and RT1 12. Cisplatin is believed to bind predominantly to the N7 position of guanine, and to form DNA inter-and intrastrand crosslinks and DNA-protein crosslinks. No correlation has been found between ATase levels and the extent of cisplatininduced DNA interstrand crosslinking in human tumour cell lines, suggesting that ATase is not involved in repair of cisplatin-induced lesions (Laurent et al., 1981; Gibson et al., 1985) . However, there is evidence for ATase activity being increased following exposure of cells to cisplatin in vitro. For example, in the H4 rat hepatoma cell line ATase levels increased approximately 4-fold 48 h after a 1 h exposure to cisplatin (Lefebvre & Laval, 1986) . In the present study, there was no evidence for increased ATase level in the cisplatinresistant subline of RT1 12. MNU sensitivity was unchanged, but RT112-CP was 2.3-fold more resistant than RT112 to mitozolomide. This suggests that RT1 12-CP has acquired resistance to crosslinking alkylating agents, but not monofunctional alkylating agents. This result implies that the increased mitozolomide resistance of RT1 12-CP is mediated by a factor other than ATase level. On the other hand, the cisplatin-resistant testicular cell line, SuSa-CP, had a higher ATase level than the parental line, and was cross-resistant to both MNU and mitozolomide. In this case, the increased ATase which may be a consequence of exposure to cisplatin, may be contributing to MNU and mitozolomide resistance in SuSa-CP.
More effective therapy for incurable cancers may result from understanding why testis tumours are sensitive to anticancer agents. We have explored some of the possible mechanisms using the model system described in this study. For example, sensitivity of testis cancers cannot be explained by cell kinetics (Walker et al., 1987; Walker, 1990 ), spontaneous or induced mutation frequency , failure to inhibit DNA synthesis (Parris et al., 1988) , glutathione-S-transferase or topoisomerase II levels (Fry et al., 1991) , level of drug binding to DNA (Walker, 1990) or levels of DNA inter-or intrastrand crosslink repair (Bedford et al., 1988) . The data presented here indicate that ATase levels are not an exclusive factor in resistance or sensitivity to nitrosoureas in these cell lines.
Future studies will focus on fundamental aspects of DNA repair and the signalling pathways that determine whether a cell survives or dies following drug-induced damage. 
